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Accepted 7 January 2009Snakebite envenoming represents a neglected tropical disease that has a heavy public
health impact, particularly in Asia, Africa and Latin America. A global initiative, aimed at
increasing antivenom production and accessibility, is being promoted by the World Health
Organization and others. This work discusses several aspects of antivenom manufacture
and control in which the proteomic analysis of snake venoms, for which the term ‘snake
venomics’ has been coined, might play a relevant supporting role. Snake venomics has
already shown its usefulness for generating knowledge at different levels (ontogenetic,
individual, and geographic) on inter- and intraspecies venom variability. This information
has applications for the quality control of venom preparations used in antivenom
manufacture. Moreover, the design of the best venom mixtures for immunization, aimed
at increasing the effectiveness of antivenoms, may also be guided by venom proteome
analysis, including molecular studies of the cross-reactivity of antivenoms and
heterologous venoms through a recently developed methodological approach termed
‘antivenomics’. Results generated by proteomic protocols should be complemented by
preclinical testing of antivenom efficacy using functional neutralization assays. Snake
venomics might be also helpful in designing alternative in vitro tests for the assessment of
antivenom efficacy that would eventually substitute current in vivo tests.
© 2009 Elsevier B.V. All rights reserved.Keywords:
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health issue on a global basis, although it has been system-
atically neglected by health authorities in many parts of the
world [1–3]. Being a pathology mainly affecting young
agricultural workers living in villages far from health care
centers in low-income countries of Africa, Asia and Latin
America, it must be regarded as a ‘neglected tropical disease’
[1]. The actual incidence of snakebite envenoming world wide
and its associated mortality are difficult to estimate, since
there are many countries where this disease is not appro-
priately reported, and since epidemiological data are often
fragmentary. Nevertheless, a recently published study esti-
mated at least 421,000 cases of envenoming and 20,000 deaths
yearly, though these largely hospital-based figures may be as
high as 1,841,000 envenomings resulting in 94,000 deaths [4],
and a previous report had estimated a total of 2.5 million
envenomings and over 125,000 deaths [5]. Even realizing that
the actual impact of this pathology is likely to be under-
estimated, because many snakebite victims seek traditional
treatment and may die at home unrecorded, it is evident that
snakebite envenoming occupies a prominent position as a
public health issue inmany regions of the world. Moreover, an
unknown percentage of snakebite victims end up with
permanent physical disability, due to local necrosis, and
with psychological sequelae, both of which greatly jeopardize
the quality of their lives. Therefore, if this pathology is
analyzed in terms of DALYs (‘disability-adjusted life years’)
lost, its impact is even greater [6].
As inmany other neglected tropical diseases [7], the task of
confronting the snakebite envenoming problem as a public
health issue demands concerted efforts at various levels:(a) It is necessary to know the actual incidence and
mortality of this disease in the affected areas.
(b) The snake species responsible for the majority of
envenomings in different parts of the world have to be
identified.
(c) Safe and effective antivenoms should be produced in
sufficient quantities, and controlled and effectively
deployed to the regions where they are needed.
(d) The access to health services has to be extended to the
remote rural locations where most snakebite accidentsoccur, thus ensuring that victims can get appropriate
medical care within the next hours after the bite.
(e) A rational and effective system for antivenom distribu-
tion and storage has to be designed in each affected
country.
(f) Health system staff in charge of treating snakebite
cases, mostly physicians and nurses, should be trained
in the basic aspects of the therapy.
The growing concern of the relevance of the snakebite
pathology has prompted an international initiative, under the
leadership of the World Health Organization [6] and involving
many participants, aimed at coordinating actions at a global
level to confront this neglected, though treatable, health
problem. One of the key aspects of this initiative is the
improvement of the quality, quantity and access of antive-
noms. Here, we review the application of proteomic methodol-
ogies, together with biological tests of toxicity, for designing,
manufacturing and controlling antivenoms, in the context of
the efforts to improve the production and access to safe and
effective antivenoms.2. The challenge of generating
effective antivenoms
The parenteral administration of animal-derived antivenoms is
the cornerstone in the therapy of snakebite envenoming world
wide [6,8,9]. The demonstration that sera from hyperimmunized
animals effectively neutralized venom-induced toxic effects was
first performed in 1894, simultaneously by Calmette and by
Phisalix and Bertrand [10]. Soon thereafter, antivenoms were
produced and successfully used for snakebite envenoming
treatment in various regions of the world [10,11]. First generation
antivenoms, produced over 100 years ago, comprised unpurified
serum from animals hyperimmunized with venom. Since then,
the technologies for antivenom production have been greatly
improved and their therapeutic effectiveness has been widely
demonstrated, particularly for controlling the systemic manifes-
tations of these envenomings [6,8,9]. Current antivenoms,mainly
produced in horses but in some cases also in donkeys and sheep,
consist of purified immunoglobulins [12] or antibody fragments
(divalent F(ab′)2 [13,14] and monovalent Fab fragments [15,16]),
which have reduced the incidence and severity of adverse
reactions associated with antivenom administration. Among
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the venoms used for immunization, ii) the design of appropriate
venom mixtures to obtain effective antivenoms, and iii) the
preclinical assessment of antivenom efficacy, are key points that
demand careful attention.
Besides the issues related with snake husbandry and
maintenance, which are out of the scope of this review, two
aspects of venom preparation are particularly relevant for
producing effective antivenoms: the adequate selection of
snake specimens for venom collection, and the correct
handling, identification, characterization, and storage of
venoms. The selection of a snake species as a candidate for
antivenom production is based on various criteria, such as: (a)
which are the snake species responsible for the largest burden
of envenoming in a geographical region?; (b) what is the range
of geographic distribution of these species?; (c) what is the
extent of geographic and ontogenetic variation of the venoms
of these species across their distribution range?; (d) what is the
venom yield obtained from a particular species?; (e) what are
the immunological relationships between these venoms and
the venoms of other taxonomically related species?; and (f )
which venoms have an immune suppressor effect?
Antivenoms present a unique characteristic compared with
other therapeutic immunoglobulin preparations, such as teta-
nus antitoxin, diphtheria antitoxin, gas gangrene antitoxin, and
anti-rabies immunoglobulins. In these, the antigens used for
immunization are the same in all regions of the world where
these immunobiologicals are manufactured. By contrast, the
immunization mixtures used for antivenom production are
specific for every country or region, due to the intraspecific
venomvariability and to the fact that different snake species are
responsible for the majority of envenomings in different
countries. The inter- and intraspecies heterogeneity in venom
composition may account for differences in the clinical
symptoms observed in human victims of envenoming by the
same snake species in different geographical regions [17,18].
Understanding the variation in antigenic constituents of
venoms from snakes of distinct geographic origin represents
thus a key challenge towards the design of novel, toxin-specific
approaches for the immunotherapy of snake bite envenoming.
On the other hand, the high levels of intra- and interspecific
variation [17],which reflects local adaptations conferring fitness
advantages to the snake population, and age-related (ontoge-
netic) changes in venom composition (possibly related to diet
differences between juvenile and adults of the same species)
[19], may also have an impact in the treatment of bite victims
and highlights the need of using pooled venoms as a substrate
for antivenom production. Intraspecific, geographic, and onto-
genetic variability in venom composition can be conveniently
analyzed using a combination of proteomic tools and toxicolo-
gical and biochemical functional assays. Knowledge of inter-
and intraspecies variability is necessary for the selection of the
regions fromwhich snake specimenshave to be collected for the
preparationof venompools. The referencevenompoolhas to be
obtained from a relatively large number of specimens collected
from different geographic regions within the distribution range
of the species.
Venom immunization protocols have changed very little
over a century and made no attempt to direct the immune
response to the most toxic venom proteins (many venomproteins are not toxic and many low molecular mass venom
proteins are highly toxic but weakly immunogenic). We
believe that toxin-specific antivenoms would improve anti-
venom dose-efficacy and, by reducing the volume of hetero-
logous IgG required to reverse venom-induced effects, would
have a better safety profile. Clearly, the design and optimiza-
tion of immunizing venom mixtures are critically dependent
upon a detailed knowledge of the venom toxin profile. In order
to explore the putative venom components, several labora-
tories have carried out transcriptomic analyses of the venom
glands of viperid (Bitis gabonica [20], Bothrops insularis [21], Bo-
throps jararacussu [22], Bothrops jararaca [23], Agkistrodon acutus
[24,25], Agkistrodon piscivorus leucostoma [26], Echis ocellatus [27] ,
Lachesis muta [28], and Sistrurus catenatus edwardsii [29]), elapid
(Oxyuranus scutellatus [30] and Austrelaps labialis [31]), and
colubrid (Philodryas olfersii [32]) snake species. Transcriptomic
investigations provide catalogues of partial and full-length
transcripts that are synthesized by the venom gland. However,
transcriptomes include translated and non-translated mRNAs,
transcripts encoding non-secreted, housekeeping, and cellular
proteins, in addition to toxin precursor genes. Moreover, the
transcriptome does not reflect within-species ontogenetic,
individual and geographic heterogeneity of venoms, which
may account for differences in the clinical symptoms observed
in envenomings. With this in mind, we have developed
proteomic-based protocols, venomics (reviewed in [33]) and
antivenomics [34,35, but see also Calvete et al. in this issue], to
define the protein composition and immunological profile of
snakevenoms,andhaveapplied theseapproaches foranalyzing
two key aspects of the variation of venom composition
(discussed below): geographic variation and ontogenetic varia-
tion, and for assessing the intra- and intergeneric cross-
reactivity of heterologous monospecific and polyspecific
antivenoms.
2.1. Snake venomics and antivenomics
Our snake venomics approach (Fig. 1) [33] starts with the
fractionation of the crude venom by reverse-phase HPLC,
followed by the initial characterization of each protein fraction
by combination of N-terminal sequencing, SDS–PAGE (or 2DE),
and mass spectrometric determination of the molecular
masses and the cysteine (SH and S-S) content. Protein
fractions showing single electrophoretic band, molecular
mass, and N-terminal sequence can be straightforwardly
assigned by BLAST analysis to a known protein family. Thus,
although few toxins from any given species are annotated in
the public-accessible databases, representative members of
most snake venom toxin families are present amongst the
∼1100 viperid toxin protein sequences belonging to 157
species deposited to date in the SwissProt/TrEMBL database
(Knowledgebase Release 56.5 of November 2008; http://us.
expasy.org/sprot/). On the other hand, protein fractions
showing heterogeneous or blocked N-termini are analyzed
by SDS–PAGE and the bands of interest subjected to auto-
mated reduction, carbamidomethylation, and in-gel tryptic
digestion. The resulting tryptic peptides are then analyzed by
MALDI–TOF mass fingerprinting followed by amino acid
sequence determination of selected doubly- and triply-charged
peptide ions by collision-induced dissociation tandem mass
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fingerprinting approach alone is unable to identify any protein
in the databases. In addition, as expected from the rapid amino
acid sequence divergence of venom proteins evolving under
accelerated evolution [36,37], with a fewexceptions, the product
ion spectra do not match any known protein using the
ProteinProspector (http://prospector.ucsf.edu) or the MASCOT
(http://www.matrixscience.com) search programs against the
1097 UniProtKB/Swiss-Prot entries from taxon Serpentes (http://
ca.expasy.org/cgi-bin/get-entries?view=full&KW=Toxin&OC=-
Serpentes). Furthermore, it is not too unusual that a product ion
spectrum matched with high MASCOT score to a particular
peptide sequence corresponds actually to a tryptic peptide of a
homologue snake toxin containing one or more nearly isobaric
amino acid substitutions. Hence, it is necessary to revise
manually all the CID–MS/MS spectra (to confirm the assigned
peptide sequence or for performing de novo sequencing), and
submit the deduced peptide ion sequences to BLAST similarity
searches. Although the lack of any complete snake genome
sequence is a serious drawback for the identification of venom
proteins, high-qualityMS/MSpeptide ion fragmentation spectra
usually yield sufficient amino acid sequence information
derived from almost complete series of sequence-specific b-
and/ory-ions tounambiguously identify ahomologueprotein in
the current databases. The combined venomics strategy allows
us to assign unambiguously all the isolated venom toxins
representing over 0.05% of the total venom proteins to known
protein families. This methodology has been applied to explore
the venom proteomes (Table 1) of the medically relevant
Tunisian vipers Cerastes cerastes, Cerastes vipera, Macrovipera le-
betina [38]; African Bitis gabonica [39], Bitis arietans [40], and Echis
ocellatus [41]; North American Sistrurus miliarius barbouri [42]
and Sistrurus catenatus subspecies [43]; the South and Central
American Lachesis sp [44]; the Armenianmountain vipersVipera
raddei and Macrovipera lebetina obtusa [45]; the arboreal Neotro-
pical pitvipers Bothriechis lateralis and Bothriechis schlegelii [34]; to
infer phylogenetic alliances within genus Bitis [46] and Sistrurus
[42]; to rationalize the envenomation profiles of Atropoides [47]
andBothrops [35] species; todefinevenom-associated taxonomic
markers [48]; and to establish themolecular basis of geographic,
individual, and ontogenetic venomvariations [49]. The state-of-
the-art of snake venomproteomics has been recently revised by
Serrano and Fox [50]. The long-termgoal of our SnakeVenomics
project is a detailed analysis of all viperid venomes.
We have coined the term “antivenomics” for the identifica-
tion of venom proteins bearing epitopes recognized by an
antivenom using proteomic techniques [34,35,51]. Antive-
nomics is based on the immunodepletion of toxins upon
incubation of whole venom with antivenom followed by the
addition of a secondary antibody. Antigen–antibody complexes
immunodepleted from the reaction mixture contain the toxins
against which antibodies in the antivenom are directed. By
contrast, venom components that remain in the supernatantFig. 1 – Snake venomics. Schematic representation of the steps t
(A) Reverse-phase chromatographic separation of the venom pro
(C) determination of the molecular masses of the proteins isolate
nanospray-ionization CID–MS/MS of selected tryptic peptide ions
Local Alignment Search Tool (BLAST). For more details consult [3are those which failed to raise antibodies in the antivenom, or
which triggered theproduction of low-affinity antibodies. These
components can be easily identified by comparison of reverse-
phaseHPLC separation of thenon-precipitated fractionwith the
HPLC pattern of the whole venom previously characterized by
venomics (Fig. 2). According to their immunoreactivity towards
antivenoms, toxinsmay be conveniently classified as: C-toxins,
completely immunodepletable toxins; P-toxins, partly immu-
nodepleted toxins; andN-toxins, non-inmunodepletedproteins
(Fig. 2B). Assuming a link between the in vitro toxin immunode-
pletion capability of an antivenom and its in vivo neutralizing
activity towards the same toxin molecules, improved immuni-
zationprotocols shouldmakeuseofmixturesof immunogens to
generate high-affinity antibodies against class P and class N
toxins. On the other hand, our antivenomics approach [34,35,51]
is simple and easy to implement in any protein chemistry
laboratory, and may thus represent another useful protocol for
investigating the immunoreactivity, and thus the potential
therapeutic usefulness, of antivenoms towards homologous
and heterologous venoms [51].
2.2. Geographic and ontogenetic variation in venom
composition: implications for the preparation of venom pools
Intraspecies variation in snake venom composition has been
extensively reported [17,18]. This phenomenon is particularly
notorious among species that have a wide distribution range.
Venom variations have been classically documented by using
conventional electrophoresis systems, such as starch gel
electrophoresis [52,53], agarose gel electrophoresis [54] and
one-dimension polyacrylamide gel electrophoresis [55,56].
More recently, the application of proteomic-based approaches
has brought novel possibilities to unveil the great complexity
and variability of snake venom composition [33,49,50,57–59].
Bothrops asper, the medically most important viperid
species from southern Mexico to northern regions of South
America [60,61], is amongst the most thoroughly studied
species concerning individual, geographic, and ontogenetic
venom variability [49]. The uplift of the mountains of lower
Central America, including the Guanacaste Mountain Range,
Central Mountain Range, and Talamanca Mountain Range
which presently separate the Caribbean and Pacific regions of
Costa Rica, occurred in the lateMiocene or early Pliocene some
8–5 million years ago (Mya) and culminated in the Pliocene
with the closure of the Panamanian Portal. This uplift may
have fragmented the original homogeneous lowland Costa
Rican herpetofauna into allopatric Caribbean and Pacific
populations. The occurrence of intraspecies variability in the
biochemical composition and pathophysiological manifesta-
tions of envenoming by snakes from different geographical
location and age has long been appreciated by herpetologists
and toxinologists. Thus, variation among the venoms of
specimens collected in the Caribbean and in the Pacific regionsypically followed in a snake venomics project.
teins; (B) SDS–PAGE of the RP–HPLC isolated proteins;
d in panel A; (D) amino acid sequence determination by
; (E) or MS/MS-derived amino acid sequence through Basic
3].
Table 1 – Overview of the relative occurrence of proteins (in percentage of the total HPLC-separated proteins) of the toxin
families in the venoms of Sistrurus catenatus catenatus (SCC), Sistrurus catenatus tergeminus (SCT), and Sistrurus catenatus
edwardsii (SCE) from USA [43]; Sistrurus miliarius barbouri (SMB) from USA [42]; the Tunisian snakes Cerastes cerastes cerastes
(CCC), Cerastes vipera (CV) andMacrovipera lebetina transmediterranea (MLT) [38]; African Bitis arietans (BA) [40]; Bitis gabonica
gabonica (BGG) [39]; Bitis gabonica rhinoceros (BGR), Bitis nasicornis (BN), and Bitis caudalis (BC) [46]; Echis ocellatus (EO) [41];
Lachesis muta (LM) [44]; Crotalus atrox (CA), and Agkistrodon contortrix contortrix (ACC) from USA (Calvete et al., unpublished);
Armenian vipers Macrovipera lebetina obtusa (Mlo), and Vipera raddei (Vr) [45]; Atropoides picadoi (Api), and Atropoides
mexicanus (Amex) [47] from Costa Rica; Bothrops asper (Bas) from the Caribbean (C) and the Pacific versants of Costa Rica [49];
Lesser Antillean pitvipers Bothrops caribbaeus (Bcar) (Santa Lucía), and Bothrops lanceolatus (Blan) (Martinique) [35]; Brazilian
Bothrops fonsecai (Bfon), and Bothrops cotiara (Bco) [48]; Bothriechis lateralis (Bolat), and Bothriechis schlegelii (Bosch) [34] from
Costa Rica; and Lachesis stenophrys (Lste) [44] from Costa Rica
Protein family Venom
SCC SCT SCE SMB CCC CV MLT BA BGG BGR BN BC EO LM CA ACC
% of total venom proteins
Disintegrins
-Long – – – – – – – 17.8 – – – – – – –
-Medium 2.5 4.2 0.9 7.7 – – – – – – – – – 6.5 –
-Dimeric – – – – 8.1 <1 6.0 – 3.4 8.5 3.5 – 4.2 – – 1.5
-Short – – – – – – <1 – – – – – 2.6 – – –
Myotoxin 0.4 <0.1 – – – – – – – – – – – – – –
C-type BPP/NP – – <0.1 <0.1 – – <1 – 2.8 0.3 – – – 14.7 2.1 <0.1
Kunitz-type inhibitor – – <0.1 <0.1 – – – 4.2 3.0 7.5 – 3.2 – – – –
Cystatin – – – – – – – 1.7 9.8 5.3 4.2 – – – – –
DC-fragment <0.1 <0.1 <0.1 1.3 – – 1.0 – 0.5 0.6 <0.1 – 1.7 – – <0.1
NGF/sv VEGF <0.1 <0.1 <0.1 <0.1 – – 2.1 – 1.0 – – – – – – –
Ohanin-like – – – – – – – – – – – – – – – <0.1
CRISP 0.8 1.3 10.7 2.9 – – – – 2.0 1.2 1.3 1.2 1.5 1.8 4.2 –
PLA2 29.9 31.6 13.7 32.5 20.0 21.1 4.0 4.3 11.4 4.8 20.1 59.8 12.6 8.7 16.3 18.5
Serine proteinase 18.2 20.4 24.4 17.1 9.1 20.0 9.2 19.5 26.4 23.9 21.9 15.1 2.0 31.2 10.1 13.8
C-type lectin-like <0.1 <0.1 <0.1 <0.1 24.0 0.9 10.1 13.2 14.3 14.1 4.2 4.9 7.0 8.1 1.6 –
L-amino acid oxidase 4.2 1.6 2.5 2.1 12.0 9.0 – – 1.3 2.2 3.2 1.7 1.4 2.7 8.0 2.2
Zn2+-metalloproteinase 43.8 40.6 48.6 36.1 37.0 48.1 67.1 38.5 22.9 30.8 40.9 11.5 67.0 31.9 51.1 63.6
Protein family Mlo Vr Api Amex Bas(C) Bas(P) Bcar Blan Bco Bfon Bolat Bosch Lste
% of total venom proteins
Disintegrins
-Long – – – – – – 1.5 – – – – – –
-Medium – – <0.1 2.5 2.1 1.4 – – 1.2 4.4 – – –
-Dimeric 8.5 9.7 – – – – – – – – – – –
-Short 2.8 – – – – – – – – – – – –
Myotoxin – – – – – – – – – – – – –
C-typeBPPP 5.3 6.0 1.8 8.6 – – – – – – 11.1 13.4 14.7
Kunitz-type inhibitor – 0.1 – – – – – – – – – – –
Kazal-type inhibitor – – – – – – – – – – – 8.3 –
Cystatin – – – – – – – – – – – – –
DC-fragment 1.7 0.1 <0.1 <0.1 <0.1 <0.1 <0.2 – 0.5 0.7 – – –
NGF/svVEGF – 2.4 <0.1 <0.1 – – – – 3.3 3.9 0.5 – 0.4
Ohanin-like – – – – – – – – – – – – –
3-Finger toxin – – – <0.1 – – – – – – – – –
CRISP 2.6 7.4 4.8 1.9 0.1 0.1 2.6 – 3.6 2.4 6.5 2.1 –
PLA2 14.6 23.8 9.5 36.5 28.8 45.1 12.8 8.6 – 30.1 8.7 43.8 12.3
Serine proteinase 14.9 8.4 13.5 22.0 18.2 4.4 4.7 14.4 14.4 4.1 11.3 5.8 25.6
C-type lectin-like 14.8 9.6 1.8 1.3 0.5 0.5 – <0.1 <0.1 9.8 0.9 – 3.6
L-amino acid oxidase 1.7 0.2 2.2 9.1 9.2 4.6 8.4 2.8 3.8 1.9 6.1 8.9 5.3
Zn2+-metalloproteinase 32.1 31.6 66.4 18.2 41.0 44.0 68.6 74.3 73.1 42.5 55.1 17.7 38.2
Major toxin families in each venom are highlighted in boldface.
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marked variation between venoms of neonate and adult speci-
mens was also described [54]. However, only recently, Alape-
Girón and colleagues [49] used a venomics approach to define in
detail the molecular bases of B. asper complex geographic and
ontogenetic changes in venom toxin composition. Using asimilarity coefficient, it was estimated that the similarity of
venom proteins between the Caribbean and the Pacific B. asper
populations may be around 52%. Notably, reverse-phase HPLC
separation provided an unambiguous profile for tracing the
geographic origin of Costa Rican B. asper snakes (Fig. 3). All
major venom protein families appeared to be subjected to
Fig. 2 – Venomics and antivenomics. Panel A displays the
reverse-phase HPLC separation of the venom proteins from
Bothrops lanceolatus (fromMartinique). For the proteomic
characterizationof thevenom,chromatographic fractionswere
collected manually and submitted to N-terminal sequencing,
molecular mass determination by ESI mass spectrometry and
SDS–PAGE under nonreduced and reduced conditions (insert)
[35]. Protein bands were excised and characterized by mass
fingerprinting andCID–MS/MS [33,35]. SP, serine proteinase; PI
and PIII, snake venom Zn2+-metalloproteinases of classes PI
andPIII, respectively [117]; LAO, L-aminoacidoxidase. Panel B,
immunodepletion of B. lanceolatus venom proteins by
polyvalent antivenom. Reverse-phase separation of soluble B.
lanceolatus venom proteins recovered after incubation of the
venomwith the Costa Rican polyvalent (Crotalinae) ICP
antivenom followed by rabbit anti-horse IgG antiserum and
immunoprecipitation [35]. p, partly immunodepleted toxins;n,
non-immunoprecipitated proteins. Insert: Western
blot analysis of the reactivity of the antivenom. (A) SDS–PAGE
separation of the various protein bands separated by HPLC.
(B) Electrotransferred replica of A onto nitrocellulose
membrane, followed by Ponceau Red staining. (C) Detection by
Western blot of venom bands using the polyvalent ICP
antivenom;proteinbandsnot recognizedby theantivenomare
framed in broken-line circles. Adapted from [35].
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tion. The occurrence of intraspecific individual allopatric
variability highlights the concept that this species should be
considered as a group ofmetapopulations. Analysis of pooled
venoms of neonate specimens from Caribbean and Pacific
regions with those of adult snakes from the same geographi-
cal region revealed prominent ontogenetic changes in both
geographical populations. Major ontogenetic changes
appeared to be a shift from a PIII-snake venom metallopro-
teinase (SVMP)-rich to a PI-SVMP-rich venom, and the
secretion in adults of a distinct set of phospholipase A2
(PLA2) molecules (Lys49-PLA2 homologues) present in very
low amounts in the neonates (Fig. 3). In addition, the
ontogenetic venom composition shift resulted in increasing
venom complexity, indicating that the requirement for the
venom to immobilize prey and initiate digestion may change
with the size (age) of the snake. The higher content of P-III
SVMPs in venoms of neonates than in those of adults is in line
with their reported more potent hemorrhagic activity [54,62].
Further, the higher content of Lys49 phospholipase A2
homologues in the venom of adults than in those of neonates
is in agreement with the higher myotoxic activity of the
former [54]. Besides its ecological and taxonomic implica-
tions, geographical venom variability may have an impact in
the treatment of snakebite victims and in the selection of
specimens for antivenom production. The occurrence of
ontogenetic, geographic, and individual intraspecific venom
variability highlights the necessity of using pooled venoms as
a representative sample for antivenom manufacture.
Viperid venom variability appears to be the rule rather than
the exception. Examples of intraspecies variability in the venoms
of medically-relevant snakes are those of Daboia russelli [63], Cro-
talus scutulatus [64], Echis carinatus and E. coloratus [65], Notechis
ater and N. scutatus [66], and Bothrops jararaca [56,67]. The venom
of the subspecies of the neotropical rattlesnake Crotalus durissus
represents a further and illustrative example of phenotypic
variation [68–71] as anadaptive trait duringC.durissus rattlesnake
invasion of South America. The Central American population of
adult C. simus, formerly classified as C. d. durissus [61], has a
venom whose main activities are local tissue damage, hemor-
rhage, coagulopathy and cardiovascular shock. Adult C. simus
venom is largely devoid of neurotoxic and systemic myotoxic
activities [68–70]. On the contrary, the venomof newbornC. simus
resembles that of the SouthAmerican rattlesnakeC. d. terrificus in
that both are devoid of hemorrhagic activity and exert potent
neurotoxic and myotoxic effects [68,70]. The characteristic
pathophysiological picture of neurotoxicity, systemic myotoxi-
cityandacute renal failure secondary tomyoglobinaccumulation
in the kidneys, associated with C. d. terrificus envenomation [72],
are all consequences of the neurotoxic and myotoxic effects of
crotoxin, aneurotoxicPLA2heterodimeric complex,whichcauses
progressiveparalysis andmyonecrosis [73,74]. Thevenomsof the
subspecies C. d. cumanensis and C. d. ruruima, which inhabit
northern regions of South America, exhibit a mixed pattern, as
they induceneurotoxicity andhemorrhage [70,75,76].Wüster and
colleagues have traced the dispersal ofC. durissus fromCentral to
SouthAmerica [77]. Their phylogeographical pattern is consistent
with a stepwise colonization progressing from a northern centre
oforigin inMexico, along theCentralAmerican Isthmus, followed
bymore rapid dispersal into northern South America and across
Fig. 3 – Geographical variation and ontogenetic changes in B. asper venom composition. Panels A and B, reverse-phase HPLC
separations and overall protein compositions (insets) of the venoms from neonate B. asper specimens from the Caribbean and
the Pacific versants of Costa Rica, respectively. Panels C and D, reverse-phase HPLC separations and overall protein
compositions (insets) of the venoms from adult B. asper specimens from the Caribbean and the Pacific versants of Costa Rica,
respectively. Prominent ontogenetic changes in both geographical populations, which are highlighted with arrows (proteins
whose expression is greatly enhanced in adult venom) and asterisks (proteins uniquely expressed in the venom of neonates),
involve a shift from a PIII-SVMP-rich to a PI-SVMP-rich venom, and the secretion in adults of a distinct set of PLA2 molecules
(K49 PLA2s). In addition, the ontogenetic venom composition shift results in increasing venom complexity. Figure adapted from
[49]. DC, Disintegrin-like/cysteine-rich fragment from PIII SVMPs; PLA2, phospholipases A2; CRISP, cysteine-rich secretory
proteins; SP, serine proteinases; LAO, L-amino acid oxidase; C-lectin, C-type lectin-like proteins.
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ongoing venomic analyses, which will be reported in detail
elsewhere, indicate that the gain of neurotoxicity associatedwith
increasing crotoxin expression represents the key axis along
which overall venom toxicity has evolved during C. durissus
invasion of South America (Fig. 4).
Assuming a link between venom toxicity and increased
crotoxin concentration, the identification of evolutionary
trends may have an impact in defining the mixture of
venoms for immunization to produce effective antivenoms.
At this respect, an antivenom manufactured in Costa Rica
using venom of the Central American rattlesnake (C. simus
simus) population, is ineffective for neutralizing both the
venom of South American C. durissus subspecies and of
newborn specimens of C. simus simus [70]. Similarly, anti-venoms produced in South America against C.d. terrificus
venom neutralize lethality of Central American venoms but
are ineffective at neutralizing the hemorrhagic activity of
venoms from genus Crotalus [70]. Such neutralizing profile is
fully explained by the proteomic characterization of Crotalus
(simus and durissus) venoms showing increasing amounts of
crotoxin in the venoms of C. durissus subspecies along the
north to south colonization pattern of this group of snakes
(Fig. 4C). This trend points to crotoxin as an adaptive trait in
the evolution of the South American rattlesnakes. Moreover,
some populations of C. d. terrificus contain crotamine, a low
molecular mass myotoxic polypeptide, whereas in popula-
tions east of the 49thmeridian and south of the 22nd parallel
the crotamine-negative C. d. durissus rattlesnakes predomi-
nate [71]. Qualitative individual differences in the venom
Fig. 4 – Crotoxin as an adaptive trait during Crotalus durissus speciation. Panels A and B display, respectively, reverse-phase
HPLC separations of the venom proteins of Crotalus simus simus (Costa Rica) and Crotalus durissus terrificus (Brazil) highlighting
peaks containing toxins responsible for the hemorrhagic (SVMPs), neurotoxic (crotoxin), and myotoxic (crotamine) activities of
the venoms. In line with their main biological effects, the hemorrhagic and tissue-damaging venom of adult C.s. simus contains
72% of SVMPs and 4% crotoxin, while the neurotoxic and myotoxic venom of C.d. terrificus comprises 60% crotoxin, 20%
crotamine, and only 5% SVMPs. Panel C, Geographical distribution of neotropical Crotalus species color-coding the crotoxin
content of their venoms. Notice a correlation between increasing expression of crotoxin in the venoms of C. durissus subspecies
along the north to south colonization pathway. Major dispersal events and their estimated dates in the evolution of the Crotalus
durissus complex have been adapted from [77]. Mya, million years ago.
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snakebite pathology and therapeutics since envenoming results
from the venom of a single snake. The application of proteomic
techniques provides useful tools to identify qualitative and
quantitative individual differences in the composition of the
venoms within populations [19]. The case of Crotalus illustrates
how the knowledge of venom variations and their geographical
distribution can lead to securing venoms with a more defined
composition for preparing venommixtures for the generation of
antivenoms effective against the venoms of rattlesnakes from
Central and South America.
2.3. Venomics aiding in taxonomy and in the correct
identification of venoms in collections
The taxonomy of snakes is a highly dynamic field of research,
and old classifications are being challenged and modified onthe basis of novel molecular analyses. Such rapidly evolving
taxonomic landscape has practical implications for antive-
nom production and use, since quite frequently the old
nomenclature remains in use in medical circles, as well as
within antivenom manufacturers. Since the sources of
venoms used for the production and quality control of
antivenoms are greatly diverse and heterogeneous, the correct
taxonomic identification of venom samples provided by
private companies or venom collections in public institutions
is sometimes uncertain and difficult to determine (see for
example [78]). Moreover, the geographic origin of the speci-
mens from which venom pools are prepared may not be
provided by venom suppliers. In some old venom collections,
the identification of the containers where valuable venom
samples are stored may have been damaged or partially
erased, thus compromising the use of this precious biological
material.
174 J O U R N A L O F P R O T E O M I C S 7 2 ( 2 0 0 9 ) 1 6 5 – 1 8 2Snake venom composition retains information on its
evolutionary history, and may thus have a potential taxo-
nomic value [46,48]. Proteomic tools represent thus an
excellent alternative to solve potential confusions in venom
identification, since the HPLC venom separation profile or 2D
SDS–PAGE constitute valuable ‘fingerprints’ of venoms. An
example is the case of two closely related pit viper species
from Central America, Atropoides mexicanus (nummifer) and
A. picadoi [61,79]. These snakes have a relatively similar
external appearance, which brings the risk of confusion in
the identification of specimens in snake collections. Fortu-
nately, the venoms of A. mexicanus (nummifer) and A. picadoi
strongly diverge in their proteome composition [47] and in
their biochemical features [80] (Fig. 5, panels A and B). We
have estimated that the similarity of venom proteins
between the two Atropoides taxa may be around 14–16%
[47]. Hence, HPLC separation or 2D SDS–PAGE analysis of
venom samples of uncertain origin can easily tell whether
the venom belongs to one or the other species, or whether it
is a mixture of both. Similarly, Bothrops represents a highly
diversified genus [81] in which some species present very
similar morphological features [61]. Species of genus Bothrops
are responsible for more fatalities in the Americas than anyFig. 5 – Snake venomics aiding in taxonomy. Panels A and B
display, respectively, the reverse-phase HPLC separation of the
venom proteins of Atropoides mexicanus (nummifer) and
Atropoides picadoi [47] The overall protein compositions are
displayed as inserts. Their distinct venom toxin compositions
provide clues for rationalizing the low hemorrhagic, coagulant,
and defibrinating activities, and the high myotoxic and
proteolytic effects evoked by A. mexicanus snakebite in
comparison to other crotaline snake venoms, and the high
hemorrhagic activity of A. picadoi. Despite the efforts of
numerous authors, phylogenetic relationships within the
subfamily Crotalinae remain controversial, particularly at the
intergeneric level. In particular, the genus Atropoides was
inferred through Bayesian phylogenetic methods to be
paraphyletic with respect to Cerrophidion and Porthidium, due
to Atropoides picadoi being distantly related to other Atropoides
species [132–134]. The proteomic characterization of venom
composition [47] supports the large divergence among A.
mexicanus (nummifer) and A. picadoi. Panels C and D show,
respectively, the reverse-phase HPLC separation of the venom
proteins of Bothrops cotiara and Bothrops fonsecai [48]. The
pictures displayed in panels C and D illustrate the high
morphological similarity between these Brazilian species.
Comparative proteomic analysis has shown that compositional
differences between their venoms can be employed as a
taxonomy signature for unambiguous species identification
independently of geographic origin andmorphological
characteristics [48]. In particular, PLA2 molecules are not
expressed in the venomof B. cotiara (Table 1) whereas venomof
B. fonsecai contains an abundant PLA2 protein (∼30% of the total
venom proteins) (Table 1) having the N-terminal sequence
NLWQFGMMIQHTTRENPLFKYFSYGCYCG and an
isotope-averaged molecular mass of 13889.9±1.3 Da [48]. This
protein (labelled with an asterisk in panel D) represents a
taxonomic marker for differentiating B. fonsecai from B. cotiara.
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species are represented in the Brazilian herpetofauna. In this
country, 28,597 snakebiteswere reported in2005, ofwhich87.5%
were related to Bothrops species (http://portal.saude.gov.br/
portal/arquivos/pdf/situacao.pdf). B. cotiara is morphologically
very similar to B. fonsecai (Fig. 5 panels C and D), although they
are not sympatric. Comparative proteomic analysis has shown
that compositional differences between their venoms can be
employed as a taxonomy signature for unambiguous species
identification independently of geographic origin and morpho-
logical characteristics ([48] but also compare panels C and D of
Fig. 5).
2.4. Quality control of venoms
An adequate preparation of snake venoms is a delicate task
that involves a correct identification and maintenance of
specimens in captivity, as well as effective protocols for
venom collection, preparation and storage. Since snake
venoms contain proteinases, venom has to be rapidly frozen
upon collection and should be properly stored following
identification. Moreover, venoms should be thawed, homo-
genized and freeze-dried for the preparation of representative
pools of many individuals. These processes, if not carried out
properly, introduce the risk of degradation and denaturation
of venom proteins. The process of freeze-drying is particularly
critical, since an inadequate freeze-drying may significantly
impair the quality of the venom. Furthermore, the storage of
freeze-dried venoms for prolonged periods of time may also
involve the risk of hydration, with the consequent impairment
in venom quality. Thus, the quality control of venoms is a
critical aspect in the preparation of venom samples for
immunization and for the quality control of antivenoms.
The quality control of venoms should include both
biochemical and pharmacological tests. Chromatographic
patterns, along with 2DE, SDS–PAGE, and proteomic techni-
ques, may be employed to detect degradation of individual
venomproteins through the appearance of novel components,
including low molecular mass hydrolysis products. These
analyses can be performed in parallel with toxicological and
functional tests such as the determination of the Median
Lethal Dose (LD50) or the quantification of enzymatic activ-
ities. It is recommended that venom preparations used in
research and antivenom manufacture and control should be
supported by a quality control analysis that ensures their
appropriateness and correct identification to the users of the
venoms.3. Proteomics in the development and selection
of adjuvants for immunization
Immunization of large mammals with venom from a single
species (for the production of monospecific antivenoms) or
from various species (for the production of polyspecific
antivenoms) involves the use of adjuvants, aimed at fostering
the immune response. Traditionally, most producers use
Freund's complete and incomplete adjuvants in the first
immunization stages, followed by aluminum salts or other
adjuvants in subsequent immunizations [83,84]. Morerecently, a variety of novel adjuvants have been developed
but have not been systematically assessed for antivenom
production. One of the main functions of adjuvants is to
promote a slow release of antigen molecules. Proteomic tools
offer an excellent alternative to analyze the kinetics of release
of various venom components in different adjuvants. Thus,
the kinetics of toxin release from the venom–adjuvant
mixture can be easily assessed in vitro by following the time-
course release of venom proteins by HPLC profiling. In this
way, the concentration and formulation of the adjuvant can be
optimized to a toxin release pattern that better fits the desired
immunization strategy.4. ‘Antivenomics’ for immunoprofiling whole
venoms and analyzing the extent of heterologous
cross-reactivity of antivenoms
Adequate treatment of snakebite envenoming is critically
dependent on the availability of antivenoms that effectively
reverse the evolution of venom-induced local and systemic
consequences of envenomation. Polyspecific antivenoms that
cover the range of snakes in a given area are preferred to
monospecific ones, because their use simplifies production,
distribution, and therapeutic procedures. However, there are
limits on the number of venoms that can be used to immunize
horses or sheep, on the amount of total venom proteins that can
be contained in a dose for immunization (“diluting” the
concentration of each toxin in the immunizing mixture) and,
once the antivenom has been produced, on the amount of total
IgGs that compriseanantivenomdose. Inaddition, somevenoms
are difficult to obtain, and some countries do not have the
adequate infrastructure or the market size to support the local
production of antivenoms. The deficit (‘crisis’) of antivenom
supply in some regions of theworld can be addressed to a certain
extent by optimizing the use of existing antivenoms and through
the design of novel immunizationmixtures for producing broad-
range polyspecific antivenoms [1–3,83,85–88]. Therefore, the
extent of immunological relationship between the venom
proteins used for immunization and the proteins present in
venomsof speciesnot included in the immunizationmixturehas
to be considered, in order to assess the coverage spectrum of
existing or newly developed antivenoms. The rationale behind
theconceptofheterologouscross-reactivityof antivenoms is that
in spite of the fact that viperid venoms comprise complex
mixtures of a large number of distinct proteins [50,58], venom
proteins belong to only a few major protein families, including
enzymes (serine proteinases, Zn2+-metalloproteinases, L-amino
acid oxidase, group II PLA2) and proteins without enzymatic
activity (disintegrins, C-type lectins, natriuretic peptides, myo-
toxins, cysteine-rich secretory proteins (CRISP), nerve and
vascular endothelium growth factors (svVEGFs), cystatin and
Kunitz-type protease inhibitors) [33]. Members of a single family
may depart from each other in their pharmacological effects but
share remarkable structure similarity, including in many cases
common epitopes.
The efficacy of monospecific and polyspecific antivenoms
is well documented in the literature [88–97]. However, the
extent of cross-protection of many monospecific or polyspe-
cific antivenoms against heterologous venoms not included in
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instance, in Central America and the northern regions of
South America, the species Bothrops asper and B. atrox inflict
the vast majority of the bites [60,61,82,98]. However, other
species from the genera Bothrops, Bothriechis, Atropoides and
Porthidium also provoke a number of accidents [61,82]. Do
antivenoms raised against B. asper or B. atrox protect against
the venoms of these other species? This question is of utmost
relevance, since the design of venom mixtures containing
these additional species would complicate antivenom manu-
facture, not only because some of these species are difficult to
obtain andmaintain in captivity, but also because their venom
yield is low [99]. A similar scenario occurs in Africa and Asia,
where the immunological relationships between medically-
relevant venoms has been studied only to a partial extent [88].
The potential value of antivenomics, togetherwith preclinical
neutralization tests, in assessing antivenom cross-reactivity is
clearly illustrated by the following examples. A highly effective
antivenom (Sanofi-Pasteur ‘Bothrofav®’) has been developed for
the treatment of envenomings byB. lanceolatus [100,101], endemic
to the Lesser Antillean island of Martinique. It exhibits an
excellent preclinical profile of neutralization [95] and its timely
administration prevents the development of the most serious
effects of envenoming, including thrombosis [100,101]. However,
the restricted availability of the antivenom in the neighboring
island of Saint Lucia and in zoos and herpetariums where these
species may be kept is a matter of concern. Gutiérrez and
colleagues [35] have performed detailed proteomic studies of the
venoms of B. caribbaeus and B. lanceolatus and have evaluated the
immunoreactivity of a Crotalinae polyvalent antivenom pro-
duced inCosta Rica (by immunization of horseswith amixture of
equal amounts of the venoms of B. asper, C. simus, and Lachesis
stenophrys) towards the venoms of B. caribbaeus and B. lanceola-
tus. This study showed that the antivenom immunodepleted
∼80% of the proteins from both B. caribbaeus and B. lanceolatus
venoms, and was effective in neutralizing the lethal, hemor-
rhagic, PLA2 and proteolytic activities of the two venoms. It also
showed that a CRISP molecule and certain serine proteinases
were not recognized by antivenom antibodies and were not
immunodepleted from the venom. Major PLA2 and PI-SVMP
molecules displayed weak immunoreactivity towards the anti-
venom and were only partially immunoprecipitated [35]. Simi-
larly, Lomonte et al. [34] have conducted an antivenomic study of
the immunoreactivity of the Costa Rican polyvalent antivenom
towards Bothriechis (lateralis and schlegelii) venoms, revealing that
L-amino acid oxidase and SVMPs represent the major antigenic
protein species inbothvenoms.The resultsprovidedaground for
rationalizing the reported protection of this polyvalent antive-
nom against the hemorrhagic, coagulant, defibrinating, case-
inolytic and fibrin(ogen)olytic activities of B. schlegelii and B.
lateralis) venoms. However, these analyses also evidenced the
limited recognition capability of the polyvalent antivenom
towards a number of Bothriechis venom components, predomi-
nantly BPPs, svVEGF, Kazal-type inhibitors, some PLA2 proteins,
some serine proteinases, and CRISP molecules. The toxicity and
potential pathophysiological relevance of such non-recognized
venom components (N-toxins) remain be assessed by in vivo
toxicity tests.
Several authors [34,35,102] have employed Western blot
analysis for assessing the immunoreactivity of antivenoms.Western blot and immunodepletion analyses yield comple-
mentary information. However, the immunochemical detec-
tion of blotted proteins provides a Yes/No response: a given
protein is recognized or not by the antivenom, and it is
essentially a non-quantitative technique. Further, proteins are
denatured to an unknown degree when solubilized by boiling
in sample buffer containing SDS. This treatment may intro-
duce artifacts such as loss of conformational epitopes and/or
artifactual recognition of non-native epitopes. On the other
hand, the degree of recognition of native proteins by the
antivenom IgGs can be easily quantitated by measuring the
amount of non-immunodepleted proteins.
Proteomics-based immunochemical analysis (antive-
nomics) provides relevant information for outlining which
venommixtures cross-react with the most important compo-
nents in medically-relevant venoms from a particular region.
This type of approachmay set the basis for the development of
antivenoms on an immunologically sound basis. However, the
actual spectrum of cross-neutralization has to be further
investigated by using toxicity preclinical tests (see below). On
the other hand, antivenomicsmay also be useful for analyzing
differences in the immune response against venoms of those
animal species usually employed for hyperimmunization,
such as horses, donkeys, sheep or camelids [8,9]. It might be
that some of these species develop a better immune response
against particular venom components than others, and this
can be easily investigated by assessing the profiles of
immunodepletion of the different venom proteins by anti-
venoms raised in the various species. Likewise, the differences
in toxin immunorecognition among individual animals of the
same species may be also studied using an antivenomic
protocol. The information gathered by this type of analysis
might contribute to the selection of the best individuals in
terms of immune response for antivenom production.5. Preclinical tests to assess antivenom efficacy
Many antivenoms are produced in the world using different
venoms in the immunization schemes [103]. Each of these
antivenoms is effective against envenomations by snakevenoms
not included in the immunizing mixtures, demonstrating
immunological cross-reactivity between related snake venoms.
A practical consequence of this fortunate circumstance is the
possibility of using theseheterologousantivenoms to circumvent
the restricted availability of species-specific antivenoms in some
regions. However, before testing in clinical trials, antivenoms
need to be evaluated experimentally, by a set of preclinical tests,
to assess their neutralizing ability against themost relevant toxic
and enzymatic activities of homologous and heterologous snake
venoms [94,104,105]. Theselectionof the tests tobeuseddepends
on the pathophysiological profile of human envenomings
characteristic of the species under investigation. For instance,
for venoms of many elapid species of genera Naja, Bungarus,
Micrurus, and Dendroaspis, whose main clinical manifestation
is neurotoxicity (i.e. muscle paralysis leading to respiratory
failure) [106,107], antivenoms should be tested against the lethal
effect of the venom, since death is theultimatemanifestationof
neurotoxicity. Other elapid venoms induce additional altera-
tions, such as myotoxicity and coagulopathy (Australian
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venoms, laboratory assays assessingmyotoxicity, coagulopathy
and dermonecrosis are required [104]. On the other hand, the
scenario for most viperid venoms is different, since envenom-
ings by these species are characterized by a complex series of
local and systemic pathophysiological alterations that include
hemorrhage, myonecrosis, dermonecrosis, defibrin(ogen)ation,
renal alterations, cardiovascular shock and, eventually, death.
In these cases, the study of the neutralization of lethality, albeit
being the most important effect, should be complemented by
the assessment of the neutralization of the additional toxic
activities [94]. Only antivenoms showing a good neutralizing
performance in preclinical testing should be authorized to go to
the clinical phases. A similar situation occurs when an
antivenomthathasbeenapproved for clinicaluse inaparticular
country for the treatment of envenomings by certain snake
species is going to be introduced in other countries or for
treating bites by other snakes, inwhich cases preclinical testing
should be performed. The ample demonstration of inter- and
intraspecies venom variability showed by proteomic studies
strongly supports this point of view. The information provided
by our antivenomics approach [34,35,51]may further contribute
to interpret the results of neutralization assays, since it enables
the identification of cross-reacting and non-reacting compo-
nents in homologous and heterologous venoms.
A number of studies have been performed to assess the
cross-reactivity of different antivenoms manufactured in
different countries. In the case of Latin America, the investiga-
tions have revealed a high-degree of cross-protection between
several antivenoms generated against Bothrops sp venoms
[35,91,93,96,97,108,109]. On the other hand, similar studies
have demonstrated that some Bothrops sp antivenoms are
effective in the neutralization of lethality of Lachesis sp.
venoms, but are ineffective in neutralizing their coagulant
and defibrin(ogen)ating activities [95,110–112]. These results
have direct implications for antivenom design: an antivenom
aimed to treat envenoming by Lachesis sp. should include this
venom in the immunizing mixture, or the coagulant enzyme
purified from the venom or expressed as a recombinant
protein. This example illustrates the relevance of performing
additional assays to the mouse lethality test in the preclinical
assessment of the neutralization profile of antivenoms.6. Perspectives: possible contribution of
proteomics in the selection of antigens for
toxin-specific immunization
The study of venom proteomes may bring another possibility
for improving immunization schemes for antivenom manu-
facture, since the experimental tools described above
(venomics and antivenomics), coupled with the characteriza-
tion of the predominant peaks and the toxicological analysis
of their activities, offer the possibility of identifying the key
toxic components in a venom. There are examples in which a
single protein, or a small set of toxins, are responsible for the
main pathophysiological activities of a venom. In such cases,
an antivenom produced using these toxins as antigens would
provide protection against the toxic effects of the whole
venom. For instance, antivenoms against sphingomyelinaseD, themain toxic component of the venomsof spiders of genus
Loxosceles, effectively neutralize the toxicity induced by the
crude venom [113,114]. A similar situation may apply to some
snake venoms, whose toxicity is based on the action of few
components. This is the case of the South American sub-
species of rattlesnakes (C. durissus spp),whose venomspresent
high concentrations of the neurotoxic phospholipase A2
complex ‘crotoxin’. This toxin, which represents up to 83% of
the total venom proteins in C. d. ruruima [Calvete et al.,
unpublished] (Fig. 3C), is responsible for three of the most
important manifestations of these envenomings, i.e. neuro-
toxicity, rhabdomyolysis, and acute renal failure secondary to
the accumulation of myoglobin in the renal tubules [73,74].
Anti-sera raised in rabbits against crotoxin and phospholipase
A2 from C. d. cascavella venom neutralize the neurotoxicity of
the venom and crotoxin [115]. Some C. durissus venoms also
induce defibrin(ogen)ation due to the action of a thrombin-like
serine proteinase [116]. Identification of this toxin by proteo-
mics and reverse-phase HPLC profilingmay allow the prepara-
tion of immunization mixtures composed of crotoxin and this
clotting enzyme, which theoretically would raise an antibody
response effective in the neutralization of the most relevant
toxicological effects induced by South American rattlesnakes.
The venoms of many species of elapid snakes of the genera
Naja, Bungarus,Micrurus, and Dendroaspis, among others, exert
a toxicological profile based on the action of pre- or post-
synaptically-acting neurotoxins. In these cases, proteomics in
conjunction with biological analyses are instrumental to
identify the predominant neurotoxins present in each parti-
cular venom, which would be the optimal antigen candidates
for immunization. Proteomic analyses have also revealed the
high concentration of SVMPs in many medically relevant
viperid snakes, such as Echis ocellatus [41], Bothrops jararaca
[58], Atropoides picadoi [47], and Bothriechis lateralis [34]
(Table 1). In agreement with these observations, SVMP-rich
venoms exert a potent hemorrhagic activity, likely due to the
action of potent multi-domain P-III hemorrhagins [117,118]. In
these cases, immunization with isolated or recombinant
SVMPs may be effective for generating antibodies able to
neutralize hemorrhagic SVMPs in a variety of viperid venoms.
Large-scale isolation of specific toxins for toxin-specific
immunization requires access to large amounts of venom,
which is often not possible. Alternatively, the structural
information gathered from venomic projects may allow
cloning and subsequent recombinant expression of the
relevant proteins. Another alternative is immunization with
specific toxin-coding DNA [119–121] or with chimeric DNA
molecules encoding a string of bioinformatics-designedmulti-
epitopes that are predicted to be highly immunogenic and
stimulate antibodies that will neutralize toxin function [122].
Exploring technologies to develop toxin-specific antivenoms
is critically dependent upon a detailed knowledge of the
venom toxin profile.7. The need to substitute animal tests for in
vitro assays: can proteomics help?
There is a growing concern for the use of mice in antivenom
testing, with the associated animal suffering and economic
178 J O U R N A L O F P R O T E O M I C S 7 2 ( 2 0 0 9 ) 1 6 5 – 1 8 2burden that represents the massive use of laboratory animals.
Sustained efforts have been performed to find alternative
tests, such as in vitro assays or tests performed in chicken
embryos before they develop pain sensitivity (reviewed in
[123]). However, the cases in which in vitro tests have been
shown to correlate with the conventional mouse test are
limited [123–128]. One reason for this failure may have to do
with the high complexity of snake venoms, whose toxicity is
due to the action of several, often many, toxins exhibiting
synergistic actions [129,130]. Proteomic tools may bring new
light into this relevant field of in vitro antivenom testing by
identifying the most relevant toxins in medically important
venoms, while the antivenomic analysis of these venomsmay
be used to assess the presence in antivenoms of high-affinity
antibodies against the relevant toxins. Once the most
important toxins in a venom have been identified, in vitro
functional tests may then be performed on nerve–muscle
preparations [115,131], on plasma clotting assays [104], on
enzymatic (proteolytic or PLA2) activities [91,125], or by using
enzyme immunoassays [127,128]. This review illustrates how
the growing body of proteomic information on snake venoms
might assist in the selection and design of in vitro tests for the
assessment of the preclinical efficacy of antivenoms. The
complexity of snake venoms implies that a single test can not
be adapted for all venoms but, instead, that the proteomics-
derived knowledge on particular venoms, coupled to the
toxicological profiles of venoms and their individual toxins,
may greatly help in the design of tests tailored for each venom
or groups of venoms. In the long term, this would contribute to
the introduction of different in vitro tests and in the reduction
of animal use and suffering associated with the performance
of in vivo assays.8. Concluding remarksThere is an urgent need to strengthen a global initiative to
confront the problem of snakebite envenoming and to reduce
the human toll associatedwith this pathology. Multiple efforts
are being promoted, and the involvement of multiple actors is
required at different levels, from the basic scientific research
realm to the public health intervention domain. Here we have
reviewed the accumulating evidence showing the potential of
proteomic tools for the improvement of antivenom design,
manufacture and control, based on a detailed and profound
knowledge of venom composition, variability and immunolo-
gical cross-reactivity. Renewed efforts have to be promoted
towards the study of the composition and actions of the
medically most important snake venoms around the world.
Since the proteomic technologies discussed here are still not
available in many countries, the organization of international
academic and public health partnerships should be fostered,
involving laboratories with the necessary technological
resources, but at the same time improving the endogenous
scientific capacity in low-income countries of Asia, Africa and
Latin America to develop proteomic research on venoms. Such
an international cooperative scenario, along with other
initiatives, would be a very positive step towards a better
understanding of venoms and antivenoms, and consequentlytowards the effective reduction of the heavy burden asso-
ciated with human envenoming by snakebite.Acknowledgements
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